NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $16.17 -0.45 (-2.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.94▼$16.9350-Day Range$13.08▼$17.5852-Week Range$7.58▼$21.44Volume34,447 shsAverage Volume45,377 shsMarket Capitalization$208.27 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Greenwich LifeSciences alerts: Email Address Greenwich LifeSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.6% Upside$36.00 Price TargetShort InterestBearish6.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 10 Articles This WeekInsider TradingAcquiring Shares$2.54 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.75) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 starsMedical Sector447th out of 936 stocksPharmaceutical Preparations Industry205th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.54% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 42.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLSI. Previous Next 4.0 News and Social Media Coverage News SentimentGreenwich LifeSciences has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Greenwich LifeSciences this week, compared to 1 article on an average week.Search Interest6 people have searched for GLSI on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,539,832.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Greenwich LifeSciences are expected to grow in the coming year, from ($0.75) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 31.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Greenwich LifeSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Greenwich LifeSciences Stock (NASDAQ:GLSI)Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Read More GLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLSI Stock News HeadlinesJuly 25 at 6:34 AM | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $23,835.00 in StockJuly 23 at 4:25 AM | insidertrades.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Acquires 1,000 Shares of StockJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 25 at 6:34 AM | americanbankingnews.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 1,500 Shares of StockJuly 22, 2024 | americanbankingnews.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Purchases 1,000 Shares of StockJune 26, 2024 | globenewswire.comGreenwich LifeSciences Set to Join Russell 2000 Index AgainJune 14, 2024 | globenewswire.comGreenwich LifeSciences Announces $2.5 Million Private PlacementMay 26, 2024 | finance.yahoo.comGreenwich LifeSciences, Inc. (GLSI)July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 20, 2024 | investorplace.comGLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024April 15, 2024 | markets.businessinsider.comGLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023March 13, 2024 | globenewswire.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025March 12, 2024 | globenewswire.comGreenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in EuropeMarch 7, 2024 | finance.yahoo.comGreenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional SharesFebruary 28, 2024 | markets.businessinsider.comExpanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-EuropeanFebruary 27, 2024 | msn.comGreenwich LifeSciences stock jumps 8% on Phase 3 study expansionFebruary 27, 2024 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 27, 2024 | globenewswire.comGreenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesSee More Headlines Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLSI CUSIPN/A CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Potential Upside/Downside+122.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-117.99% Return on Assets-113.35% Debt Debt-to-Equity RatioN/A Current Ratio14.12 Quick Ratio14.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book31.10Miscellaneous Outstanding Shares12,880,000Free Float6,072,000Market Cap$208.27 million OptionableNot Optionable Beta1.64 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Snehal S. Patel (Age 60)CEO, CFO & Director Comp: $1.09MMr. Eric Rothe (Age 48)Founder & Independent Director Comp: $65.64kDr. Frank Joseph Daugherty M.D. (Age 73)Chief Medical Officer & Director Dr. Jaye L. Thompson Ph.D. (Age 58)Vice President Clinical & Regulatory Affairs Dr. Christine T. Fischette Ph.D. (Age 73)VP of Business Development Key CompetitorsPuma BiotechnologyNASDAQ:PBYIEntasis TherapeuticsNASDAQ:ETTXStealth BioTherapeuticsNASDAQ:MITOPhibro Animal HealthNASDAQ:PAHCEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,295 shares on 7/26/2024Ownership: 0.119%Snehal PatelBought 1,500 shares on 7/23/2024Total: $23,835.00 ($15.89/share)Jaye ThompsonBought 1,000 shares on 7/18/2024Total: $16,000.00 ($16.00/share)Snehal PatelBought 174,825 shares on 6/13/2024Total: $2.50 M ($14.30/share)Vanguard Group Inc.Bought 1,420 shares on 5/10/2024Ownership: 1.732%View All Insider TransactionsView All Institutional Transactions GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $10.52 on January 1st, 2024. Since then, GLSI shares have increased by 53.7% and is now trading at $16.17. View the best growth stocks for 2024 here. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) released its earnings results on Monday, May, 20th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital acted as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional investors include Bank of New York Mellon Corp (0.12%). Insiders that own company stock include Snehal Patel, Jaye Thompson, Frank Joseph Daugherty, David Mcwilliams and Kenneth Hallock. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLSI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.